+0  (1%)
Previous Close 5.64
Open 5.66
Price To book 11.95
Market Cap 234.94M
Shares 41,073,000
Volume 204,864
Short Ratio 8.16
Av. Daily Volume 642,052

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 planned for 2017.
Rett syndrome
Phase 2a 12-month data released December 8, 2016. Trial is ongoing. Additional Phase 2/3 trial planned.
Mild to moderate Alzheimer’s disease

Latest News

  1. Can Anavex (AVXL) Run Higher on Strong Earnings Estimate Revisions?
  2. For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1
  3. Anavex Life Sciences Reports New Mechanism of Action Data Related to ANAVEX Compounds Targeting Sigma-1 Receptor
  4. Anavex Life Sciences Reports Dismissal of Appeal in the Cortina Lawsuit
  5. Anavex Life Sciences to Present at the 13th International Conference on Alzheimer's and Parkinson's Diseases AD/PD™ 2017
  6. Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk
  7. Anavex Life Sciences to Present at Oppenheimer 27th Annual Healthcare Conference
  8. Anavex Life Sciences to Present at 14th Annual BIO Asia International Conference
  9. 3 Companies That Might Not Live to See 2020
  10. 3 Companies Looking to Capitalize on Orphan Designation with Multiple Catalyst
  11. Anavex Life Sciences Strengthens Board of Directors
  12. Anavex Life Sciences’ CEO Joins BIO CEO & Investor Conference 2017 Panel “Designing Clinical Trials in 21st Century Cures Paradigm”
  13. Here's Why Anavex Life Sciences Corp. Surged Today
  14. Noble Capital Markets Initiates Research Coverage on Anavex Life Sciences Corp. (AVXL)
  15. Anavex Life Sciences reports 1Q loss
  16. Anavex Reports Fiscal First Quarter 2017 Financial Results
  17. Forget Anavex Life Sciences Corp.: These 2 Biotech Stocks Are Better Buys